Aurobindo Pharma arm Eugia Pharma gets USFDA nod for Vasopressin Injection USP by admin- Tuesday, August 16th, 2022 03:22:39 PM
Aurobindo Pharma introduced that its thoroughly owned subsidiary employer, Eugia Pharma Specialties Ltd, has obtained a very last approval from america Food & Drug Administration (USFDA) to manufacture and market Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials. Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials, to be bioequivalent and therapeutically equal to the reference listed drug (RLD), Vasostrict Injection, 20 gadgets/mL of Par Sterile Products, LLC (Par). The product is being launched Immediately. The authorized product has an estimated market size of around US$ 606 million for the twelve
months finishing June 2022, consistent with IQVIA.
This is the 146 th ANDA (consisting of 10 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) centers, production each oral and sterile strong point merchandise.
Vasopressin Injection USP is indicated for the treatment of Cardiovascular agent: vasoconstrictor